eligibility_summary
Inclusion: Advanced NSCLC needing RT to metastases, measurable lesion, age 18–70, post ≥2nd-line (≥2 wks since last therapy), ≥3‑mo survival, ECOG 0–1, adequate heart/liver/kidney and blood counts, infection‑negative, normal rheum/thyroid/ACTH, contraception, consent. Exclusion: uncontrolled brain mets, other anticancer therapy, recent steroids/immunotherapy/trials, major CV/HTN, bleeding/thrombosis, active TB/infection, transplant, CNS disease, splenectomy, pregnancy, severe allergy, substance abuse, PI judgment.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase 2 single-arm trial in advanced NSCLC after second-line failure testing three interventions: 1) Personalized neoantigen-loaded autologous dendritic cell (DC) vaccine (cell-based immunotherapy) that presents patient-specific neoantigens via MHC I/II to prime and expand CD8+ cytotoxic and CD4+ helper T cells, enhancing antigen presentation and costimulation, 2) PD-1 inhibitor (monoclonal antibody immune checkpoint inhibitor) blocking PD-1/PD-L1/PD-L2 signaling to reverse T-cell exhaustion and sustain antitumor activity, 3) Radiotherapy (external beam) inducing DNA damage and immunogenic cell death, increasing antigen release and type I IFN/STING signaling with potential abscopal effects. Targets/pathways: dendritic cells, tumor-specific T cells, PD-1 checkpoint axis, antigen presentation pathways, and irradiated tumor cells.